Information Provided By: 
Fly News Breaks for July 27, 2015
TEVA, AGN
Jul 27, 2015 | 07:51 EDT
Cowen said its model for Allergan was to focus on the pursuit of smaller complimentary transactions and the firm believes the sale of its generics business would provide massive available capital. The firm feels the capital will be used to deploy into higher margin, more durable and growing assets and thus recommends buying more Allergan shares. Cowen reiterated its Outperform rating and $350 price target on Allergan.
News For AGN;TEVA From the Last 2 Days
There are no results for your query AGN;TEVA
